All articles by Phillip Broadwith – Page 17
-
Business
Novo Nordisk to create 6000 jobs by 2022
Half of the new Danish employees will be in R&D roles
-
Business
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition
Early-stage drugs complement Merck’s own developmental portfolio
-
Business
Data sharing helps firms reduce Reach animal testing
Alternative in vitro methods slowly gaining traction for some tests
-
Business
Generics giants jostle over pain drug
Mylan and Actavis contest Teva’s generic celecoxib exclusivity
-
Business
Drug companies rapped for anticompetitive behaviour
Italian authorities demand €1.2 billion in damages from Roche, Novartis and Pfizer
-
Business
Nano risk register not necessary, says BASF
Reach covers the relevant information, and a register risks attracting unwarranted stigma
-
Business
Boehringer to settle blood thinner drug suits for $650m
Company confident in drug safety but says court cases are too risky
-
Business
Time called on Pfizer–AstraZeneca deal
Pfizer could make a fresh approach after six months under City takeover rules
-
Business
Mitsui continues reinvention efforts with two deals
Japanese firm drops organic acids in favour of lens materials
-
Business
Novartis enhances its focus with eyecare deal
Swiss firm buys rights to wet AMD drug from Ophthotech for up to $1bn
-
Business
AstraZeneca refuses Pfizer’s ‘final’ offer
Pfizer pledges not to make hostile bid direct to shareholders
-
Business
Lilly protests $450m Brazilian fine
Firm says chemicals employees were allegedly exposed to were never used at site
-
Business
Chinese police hand GSK bribery case to prosecutors
Investigation alleges senior manager ordered staff to hand out bribes
-
Business
Solvay-Ineos PVC deal passes European approval
Firms required to divest plants to maintain competition
-
Business
UK Lords urge government to take lead on fracking
Regulations holding back shale gas exploration, report says
-
Business
UK regulator warning over online herbal remedies
Products found to contain toxic metals or undeclared prescription-only drugs
-
Business
Insider trading allegations stall Sun–Ranbaxy deal
Companies deny wrongdoing in lead-up to merger announcement
-
Business
Forest Labs buys Furiex for bowel drug
Firm will immediately sell on other assets to Royalty Pharma
-
Business
BASF to cut 260 jobs in nutrition and health
Firm to sell Norwegian site and shift focus towards Asia